☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
P-III COMBI-AD Trial
Novartis Reports Results of Extended Follow-up P-III COMBI-AD Trial of Tafinlar (dabrafenib) + Mekinist (trametinib) during ESMO18
October 22, 2018
Load more...
Back to Home